Literature DB >> 15211091

Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology.

Lynn C Shaw1, Maria B Grant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15211091     DOI： 10.1023/B:REMD.0000032408.18015.b1

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


× No keyword cloud information.
  76 in total

Review 1.  Antisense IGF and antisense IGF-IR therapy of malignancy.

Authors:  H Wang; Y Liu; L Wei; Y Guo
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

2.  The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor.

Authors:  S M Leal; Q Liu; S S Huang; J S Huang
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

3.  Regulation of vascular endothelial growth factor expression by insulin-like growth factor I.

Authors:  R S Punglia; M Lu; J Hsu; M Kuroki; M J Tolentino; K Keough; A P Levy; N S Levy; M A Goldberg; R J D'Amato; A P Adamis
Journal:  Diabetes       Date:  1997-10       Impact factor: 9.461

4.  The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression.

Authors:  D Coppola; B Saunders; L Fu; W Mao; S V Nicosia
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

5.  Transferrin is an insulin-like growth factor-binding protein-3 binding protein.

Authors:  S A Weinzimer; T B Gibson; P F Collett-Solberg; A Khare; B Liu; P Cohen
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

6.  Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines.

Authors:  G Zugmaier; B W Ennis; B Deschauer; D Katz; C Knabbe; G Wilding; P Daly; M E Lippman; R B Dickson
Journal:  J Cell Physiol       Date:  1989-11       Impact factor: 6.384

7.  Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin.

Authors:  P G Campbell; S K Durham; J D Hayes; A Suwanichkul; D R Powell
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

8.  Reversion of 'early worsening' of diabetic retinopathy by deliberate restoration of poor metabolic control.

Authors:  E Chantelau; R Meyer-Schwickerath
Journal:  Ophthalmologica       Date:  2003 Sep-Oct       Impact factor: 3.250

Review 9.  Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks.

Authors:  J W Kolaczynski; J F Caro
Journal:  Ann Intern Med       Date:  1994-01-01       Impact factor: 25.391

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245
View more
  11 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Does diabetes therapy influence the risk of cancer?

Authors:  U Smith; E A M Gale
Journal:  Diabetologia       Date:  2009-09       Impact factor: 10.122

Review 3.  IGF-I in the clinics: Use in retinopathy of prematurity.

Authors:  Ann Hellström; David Ley; Ingrid Hansen-Pupp; Boubou Hallberg; Luca A Ramenghi; Chatarina Löfqvist; Lois E H Smith; Anna-Lena Hård
Journal:  Growth Horm IGF Res       Date:  2016-09-28       Impact factor: 2.372

4.  IGF-1R Regulates the Extracellular Level of Active MMP-2, Pathological Neovascularization, and Functionality in Retinas of OIR Mouse Model.

Authors:  Valeria E Lorenc; Paula V Subirada Caldarone; María C Paz; Darío G Ferrer; José D Luna; Gustavo A Chiabrando; María C Sánchez
Journal:  Mol Neurobiol       Date:  2017-01-17       Impact factor: 5.590

5.  Insulin-like growth factor I (IGF-I)-induced chronic gliosis and retinal stress lead to neurodegeneration in a mouse model of retinopathy.

Authors:  Pilar Villacampa; Albert Ribera; Sandra Motas; Laura Ramírez; Miquel García; Pedro de la Villa; Virginia Haurigot; Fatima Bosch
Journal:  J Biol Chem       Date:  2013-04-25       Impact factor: 5.157

Review 6.  Diabetic microangiopathy: IGFBP control endothelial cell growth by a common mechanism in spite of their species specificity and tissue peculiarity.

Authors:  S Giannini; B Cresci; C Manuelli; L Pala; C M Rotella
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

7.  RTEF-1 attenuates blood glucose levels by regulating insulin-like growth factor binding protein-1 in the endothelium.

Authors:  Angela F Messmer-Blust; Melissa J Philbrick; Shuzhen Guo; Jiaping Wu; Ping He; Shaodong Guo; Jian Li
Journal:  Circ Res       Date:  2012-07-25       Impact factor: 17.367

Review 8.  Role of the retinal vascular endothelial cell in ocular disease.

Authors:  Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith
Journal:  Prog Retin Eye Res       Date:  2012-09-11       Impact factor: 21.198

9.  Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown.

Authors:  Virginia Haurigot; Pilar Villacampa; Albert Ribera; Cristina Llombart; Assumpcio Bosch; Victor Nacher; David Ramos; Eduard Ayuso; José C Segovia; Juan A Bueren; Jesus Ruberte; Fatima Bosch
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

10.  Insulin-like growth factor binding protein-3 in preterm infants with retinopathy of prematurity.

Authors:  Manizheh Mostafa Gharehbaghi; Ali Peirovifar; Karim Sadeghi; Haleh Mostafidi
Journal:  Indian J Ophthalmol       Date:  2012 Nov-Dec       Impact factor: 1.848
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.